KSI-301, a therapy for patients with nAMD, did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks; however, it was safe and well-tolerated with no new or unexpected safety signals.
Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.
According to the company, it is developing elamipretide for treatment of extra-foveal geographic atrophy under U.S. FDA Fast Track designation.
At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.
AM712 is a novel bispecific biologic molecule specifically designed for ocular use. In pre-clinical studies, it demonstrated efficacy, ocular pharmacokinetics, and the desired safety profile supporting clinical exploration.
At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.
Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wet AMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
A brief overview of findings presented at the 2022 Angiogenesis, Exudation and Degeneration meeting hosted by Bascom Palmer.
Dr. Carl Regillo discusses the 100-week results of KESTREL and KITE, two pivotal Phase 3 studies for brolucizumab for the treatment of diabetic macular edema.
Most patients (95%) with the PDS implanted did not need supplemental treatment before the refills, indicating the persistence and durability of the treatment.
Most patients (95%) with the PDS implanted did not need supplemental treatment before the refills, indicating the persistence and durability of the treatment.
Previously treated patients showed significantly reduced treatment burden.
At Angiogenesis, Dr. SriniVas R. Sadda discusses how choriocapillaris may predict the rate of progression of atrophy.
At Angiogenesis, Dr. SriniVas R. Sadda discusses how choriocapillaris may predict the rate of progression of atrophy.
In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared to sham treatment.
In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.
Dr. Nadia K. Waheed reviews the latest updates on the FOCUS trial, evaluating AAV-based viral vector GT005 for the treatment of geographic atrophy.
Dr. Nadia K. Waheed reviews the latest updates on the FOCUS trial, evaluating AAV-based viral vector GT005 for the treatment of geographic atrophy.
This study showed that an investigational subretinal implant, CPCB-RPE1, containing allogeneic human embryonic stem cell-derived RPE cells, was safe and well-tolerated by patients with dry AMD.
Dr. David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
Dr. David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
NGM621 is a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.
The latest invention from Mark S. Humayun, MD, PhD, brings hope to sufferers of age-related macular degeneration, a common type of blindness.
NGM621 is a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.
